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Abstract
Chronic infection by Helicobacter pylori is a major risk factor for gastric adenocarcinoma and mucosa-associated lymphoid tissue lym-
phoma. H. pylori possesses a set of virulence factors, including the CagA effector, which interferes with intracellular signalling pathways
and mediates phenotypic alterations, strongly evoking neoplasic transformation. MicroRNAs (miRNAs) are post-transcriptional regula-
tors of gene expression involved in development, cell proliferation and immune responses. miRNAs are frequently altered in cancers,
revealing their functions as oncogenes or tumour suppressors. However, the role, if any, that miRNAs play in the host cell responses
to H. pylori remains unknown. This review considers the possible involvement of some miRNAs, including miR-146, miR-155, miR-21,
miR-27a, miR-106-93-25 and miR-221-222 clusters and the miR-200 family in H. pylori-induced infection and gastric cancers. Further
exploration of miRNA-mediated gene silencing, taking into account the relationship between host targets and bacterial effectors, will
most certainly bring new insights into the control of gene expression in human gastric cells chronically infected by H. pylori.
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Gastric cancer is the second leading cause of cancer-related
death worldwide [1]. The major risk factor associated with
gastric adenocarcinoma is infection by Helicobacter pylori, a
Gram-negative microaerophilic bacterium that colonizes the
gastric mucosa of approximatively 50% of the human popula-
tion. It induces a chronic gastric inﬂammation, which evolves
in approximatively 10% of cases towards more severe forms
of gastric diseases, such as peptic ulcer, gastric carcinoma
and mucosa-associated lymphoid tissue (MALT) lymphoma.
Chronic inﬂammation represents a major pathological back-
ground for human malignancies. H. pylori possesses a set of
virulence factors for colonizing the gastric mucosa and estab-
lishing a chronic infection. Notably, the most virulent strains
harbour the cag pathogenicity island (cag PAI), which
encodes a type IV secretion system (T4SS) and the protein
CagA. Once translocated into the host cell cytoplasm, CagA
is phosphorylated by Src kinases and can subsequently inter-
fere with intracellular signalling pathways, leading to cell
proliferation, cytoskeletal rearrangement, cell–cell adhesion
loss, extracellular matrix remodelling and b-catenin pathway
activation [2]. All of these CagA-mediated phenotypic altera-
tions strongly suggest a role of this bacterial effector in cell
transformation. Other virulence factors associated with
H. pylori pathogenesis are adhesins (BabA, HopZ, HopH), the
vacuolating cytotoxin VacA, tumour necrosis factor (TNF)-
a-inducing protein [3], and the T4SS, which interacts with
integrins and injects the CagA protein and components of
the peptidoglycan into the host cells [4,5].
Discovered approximately 10 years ago, microRNAs
(miRNAs) are currently considered as crucial post-tran-
scriptional regulators of gene expression. Their roles
in development, cell proliferation and differentiation are
widely recognized, as is their importance in the regulation
of immune responses [6]. Furthermore, miRNAs are fre-
quently altered in cancer cells and reveal their functions as
either oncogenes or tumour suppressors [7,8]. The emerg-
ing role of miRNAs in diverse and fundamental cellular
mechanisms suggests that proper control of these regula-
tory elements is essential for the maintenance of a
nonpathological state.
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Do miRNAs play any role in the host cell responses to
H. pylori infection? To date, only one miRNA has been
reported to be up-regulated in H. pylori-infected cells [9].
However, the abundant literature on changes in gene expres-
sion in cells and tissues infected by this pathogen, the grow-
ing amount of data on miRNAs implicated in cancer,
including gastric cancer and lymphomas, and in infection,
make it worthwhile to study the possible involvement of
other miRNAs in the response of the gastric mucosa to
H. pylori infection. This could provide additional insights into
the mechanisms by which this pathogen causes chronic
inﬂammation and gastric pathologies. This review summarizes
the currently available knowledge concerning the role of
miRNAs in infection and carcinogenesis and raises the ques-
tion of the possible involvement of some miRNA in H. pylori-
induced infection and gastric cancer.
Human miRNA Biogenesis
MiRNAs are small noncoding RNAs that regulate gene
expression by post-transcriptional silencing, most usually
after binding to the 3¢ untranslated region (UTR) of mRNAs.
MiRNAs are generated from sequential processing of longer
primary transcripts by Drosha and Dicer RNAses (Fig. 1).
Active mature miRNAs are single-stranded RNA, 20–25
nucleotides long, integrated in a RNA-induced silencing com-
plex and associated with the 3¢ UTR of speciﬁc target
mRNAs to suppress their translation. RNA silencing could
involve P-bodies, where the miRNA-targeted mRNAs would
be relocalized [10,11].
Bioinformatic analyses lead to an estimation that as many
as 30% of human genes are targets of miRNA [12]. Cur-
rently, there are 678 mature human miRNA sequences listed
in the miRNA registry (http://www.microrna.sanger.ac.uk),
with approximately 1000 predicted miRNAs, each potentially
targeting approximately 200 genes.
miRNAs in the Host Response to
Pathogens
Innate immunity and miRNAs
Cells recognize invading pathogens and/or their secreted
effectors through ‘pathogen-recognition molecules’, known
as Toll-like receptors (TLR) and Nod-like receptors (NLR),
located on the cell membrane and in the cytoplasm, respec-
tively. Pathogen-recognition molecules subsequently activate
a set of adaptor proteins and transcription factors mediating
FIG. 1. Most microRNAs (miRNAs) are transcribed by RNA poly-
merase II (with a few exceptions that are transcribed by RNApol III)
as primary transcripts (pri-miRNAs) from independent genes or gene
clusters, or sequences included in mRNA introns. These long
pri-miRNAs are processed into approximately 70-nucleotide long
precursor hairpins (pre-miRNAs) by the nuclear microprocessor
complex (MiPC) composed notably of the RNase III-type Drosha en-
doribonuclease, in association with the double-stranded RNA-binding
protein DGCR8 (DiGeorge syndrome critical region gene 8). Inter-
estingly, some are generated in a microprocessor-independent fash-
ion as spliced-out introns (mirtrons) [54]. Exportin5 then transports
pre-miRNAs to the cytoplasm where they are cleaved into 20–25-bp
miRNA duplexes by another RNase III-type endonuclease, Dicer,
complexed in particular to TRBP (TAR RNA-binding protein) and
the PKR activator PACT. One strand is selected to function as
mature miRNA and is incorporated into the miRNA-induced silenc-
ing complex (RISC), which contains members of the argonaute pro-
tein family, whereas the other strand is degraded. The miRNA-RISC
complex associates with the 3¢ untranslated region (3¢ UTR) of
targeted mRNAs. The target mRNA is then silenced by translational
inhibition or RNA degradation. This RNA silencing could implicate
the P-bodies where the miRNA-mRNA duplexes could be re-local-
ized [10,11].
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host innate immunity such as the nuclear factor-jB (NF-jB)
and the activator protein 1 (AP-1) pathways. NF-jB has been
identiﬁed as a potential molecular bridge between inﬂamma-
tion and cancer because improper NF-jB activation transac-
tivates several target genes harbouring inﬂammatory (e.g.
cyclooxygenease 2, inducible nitric oxide synthase, TNF-a),
anti-apoptotic (e.g. cIAP1 and 2, XIAP, Bcl-2, Bcl-3, Bcl-xL),
cell cycle regulatory (e.g. cyclin D1) and proangiogenic (e.g.
vascular endothelial growth factor, angiopoietin) functions,
and/or down-regulates apoptosis-inducing genes (e.g. p53,
Bax, Bad), thus contributing to tumourigenesis [13].
The involvement of miRNAs in the innate and adaptative
immune responses is now established. MiR-155 and
miR-146a are involved in innate immunity by regulating the
acute inﬂammatory response in monocyte/macrophages after
pathogen recognition by TLR. MiR-146a, induced by NF-jB
via TLR2, 4, 5 signalling, targets the TLR-signalling adaptators
IRAK1 and TRAF6, placing this miRNA into a negative-feed-
back loop, regulating TLR signalling in response to bacterial
products [14]. MiR-155 is induced during both bacterial and
viral infection in myeloid cells through the TLR pathway, as
well as by pro-inﬂammatory cytokines. It down-regulates
FADD, RIP and IKK, other components of the TLR signalling
mechanism [15]. Conversely, miR-125b is decreased in paral-
lel to miR-155 up-regulation. MiR-125b represses TNF-a syn-
thesis, ensuring the suppression of this pro-inﬂammatory
cytokine under noninfectious conditions, whereas its
decrease allows for TNF-a production to occur after TLR
stimulation [16]. MiR-155 is up-regulated in activated B and
T cells and in the germinal B cell centre [17]. This miRNA is
best known for its involvement in the development of B-cell
malignancies; it has been found at high levels in human B cell
lymphomas [18,19], and enforced miR-155 overexpression in
mouse B cells is sufﬁcient to trigger murine B cell lymphoma
[20]. It is encoded in the BIC locus, which represents a com-
mon viral integration site in chickens. Because of its involve-
ment in both the innate immune response and its oncogenic
potential, miR-155 could comprise an additional bridge
between inﬂammation and cancer [21].
Exploitation of Host-cell miRNAs Pathways
by Pathogens
Microbes have evolved strategies to circumvent the host
immune response with the aim of establishing a sustainable
infection. This includes the development of effectors that are
able to interfere with the miRNA pathway. Viruses provide
several examples of proteins hijacking miRNAs, thus favour-
ing virus replication: the tomato bushy stunt virus p19 [22],
the mammalian Nodamura virus B2 [23], or the primate
foamy virus I Tas proteins [24]. Pathogens can also take
advantage of host cell miRNAs; for example, the liver-speciﬁc
miR-122 enhances hepatitis C virus replication rate [25]...
The parasite Plasmodium falciparum better survives in Anophe-
les gambia when miRNA maturation is impaired [26].
Bacterial suppressors of the miRNA network have been
recently identiﬁed in plants [27]. It was reported that Pseudo-
monas syringae, a Gram-negative bacterium, injected bacterial
effectors through a type III secretion system to supress
PAMP-responsive miRNAs. This repression took place at
multiple levels: transcription, miRNA biogenesis, stability and
activity. This is the ﬁrst example of a bacterium hijacking the
miRNA system, leading to the possibility that human patho-
genic bacteria, including H. pylori, have also evolved to sup-
press miRNA silencing to ensure persistent infection.
miRNAs and Gastric Cancers
MiR-21-induced expression upon H. pylori infection
MiR-21 is consistently up-regulated in solid human cancers,
including the stomach, as compared with matching noncan-
cerous tissue [19]. Direct targets of miR-21 have been iden-
tiﬁed, with all of them being tumour suppressors: the PTEN
phosphatase [28], the actin-binding protein tropomyosin 1
[29] and the reversion-inducing-cystein-rich protein with
Kazal motifs [30]. Thus, this single miRNA provides a
signiﬁcant survival advantage to cells upon deregulation.
In a recent study, Zhang et al. [9] found that miR-21 was
over-expressed in gastric cancer tissue samples and cell lines,
as well as in chronically H. pylori-infected gastric epithelium
tissue, as opposed to noninfected tissue. MiR-21 was also
up-regulated in cultured gastric epithelial cells upon co-cul-
ture with H. pylori. This is the ﬁrst evidence of miRNA mod-
ulation upon H. pylori infection. Zhang et al. [9] showed that
over-expression of miR-21 promoted cell proliferation and
migration and inhibited apoptosis in this cell line. AP-1 and
the signal transducer and activator of transcription 3
(STAT3) are able to induce miR-21 [31,32]. NF-jB activation
and interleukin (IL)-6 secretion in the gastric mucosa, which
activate AP-1 and STAT3, respectively, could explain miR-21
up-regulation during H. pylori infection.
Speciﬁc over-expression of miR-106b, -93, -25 in
gastric cancers
In patients suffering from H. pylori-induced gastritis, a rela-
tionship was found among cagA-positive strains, epithelial
proliferation and inﬂammatory reaction, mostly located at
the antral lesser curvature, an area where most carcinoma
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arise. The intricate balance of pro- and anti-inﬂammatory
cytokines in chronic inﬂammation may mediate the outcome
of H. pylori infection by affecting cell proliferation and apop-
tosis. Among the anti-inﬂammatory cytokines, transforming
growth factor (TGF) b is involved in mucosal immunity and
morphogenetic programming, comprising a cross-talk
between the epithelial and stromal compartments that guides
gastrointestinal cells toward proliferation, differentiation and
apoptosis, thus controlling the physiological turnover of epi-
thelial cells [33].
The downstream effectors of TGFb-dependent cell cycle
arrest and apoptosis are the cyclin-dependent kinase inhibi-
tor p21CIP1/WAF1 and the pro-apoptotic factor Bim, respec-
tively. TGFb induced a marked down-regulation of the E2F1
protein and Mcm7 mRNA as cells physiologically underwent
G1/S cell cycle arrest. Furthermore, gastric tumours of
diffuse type are characterized by E2F1 up-regulation and
TGF-b resistance. In a microarray analysis of miRNAs asso-
ciated with gastric mucosa inﬂammation, preneoplastic
lesions or carcinomas, Petrocca et al. [35] identiﬁed several
miRNAs that are associated with chronic inﬂammation,
including up-regulated miRNAs (miR-1, miR-155) and down-
regulated miRNAs (miR-205, -303, -202, -20 and 26b), as
well as others that were up-regulated in human gastric
adenocarcinomas, namely miR-106b, miR-93 and miR-25.
Petrocca et al. [35] provide evidence that miR-106b, miR-93
and miR-25 alter the physiological response of gastric can-
cer cells to TGF-b, affecting both the cell cycle and apop-
tosis [35,36]. E2F1 is a transcriptional factor required for
the G1/S transition. In resting cells, it is sequestered by the
unphosphorylated retinoblastoma protein pRb. Although
E2F1 self-activates its own promoter through a positive-
feedback loop, it also transactivates a cluster of intronic
miRNAs, miR-106b, miR-93 and miR-25, hosted in the
Mcm7 gene, inducing their accumulation in gastric primary
tumours and gastric epithelial cell lines [35,36]. Conversely,
miR-106b and miR-93 decrease E2F1 expression, establish-
ing a negative-feedback loop preventing E2F1 self-activation.
MiR-106b, miR-93 and miR-25 also silence p21CIP1/WAF1 in
addition to E2F1, leading to a decreased response of gastric
cells to TGFb (i.e. cells continue to grow despite a high
level of the cytokine).
Prolonged exposure to TGFb leads to apoptosis. MiR-25,
but not miR-106b or miR-93, negatively inﬂuences Bim in
gastric cell lines through a post-transcriptional regulatory
mechanism. Anti-apoptotic and pro-apoptotic responses
associated with miR-106b, -93 and -25 emerge in the late
phase of TGFb stimulation, when cell cycle arrest is revoked
and apoptosis becomes the dominant process characterizing
the response of a gastric cell to TGFb. This is relevant in a
gastric cancer model because impairment of the TGFb-medi-
ated tumour suppressor pathway is a critical step in the
development of gastric tumours.
A paralogue to the miR-106b-25 cluster is the miR-17-92
cluster at chromosome 13q31, encoding miR-17, miR-18a,
miR-19a, miR-20a, miR-19b-1 and miR-92-1. The miR-17-92
cluster also harbours an oncogenic potential; indeed, miR-17-
92 transcripts are elevated in B cell lymphomas [37] as well
as in lung, colon and pancreas carcinomas [19], and ectopic
expression of miR-17-92 causes lymphoproliferative disease
and autoimmunity [38]. miRNAs encoded by that cluster are
up-regulated in gastric tumour samples compared to the nor-
mal counterpart [39].
In addition to the miR-106b-25 cluster, the miR-221-222
cluster also has highly increased gastric tumour samples and,
interestingly, the expression patterns of the two clusters
correlate with each other [39]. Although p21CIP1/WAF1 was
conﬁrmed as miR-106b and miR-93 targets, there was
evidence that mir-25, mir-221 and mir-222 silenced p57kip2
and p27kip1, which are other cyclin-dependent-kinase inhibi-
tors of the cip/kip family. Thus, these two clusters appear to
be functionally co-regulated to facilitate G1/S transition in
gastric tumour cells.
Putative Role of miRNAs in H. pylori
Infection and Gastric Cancer
MiR-146, miR-155 and immunity
In H. pylori infection, the gastric epithelial cells provide the
ﬁrst line of defence against this noninvasive pathogen. In
these cells, the innate immune response is characterized by
the activation of the NF-jB pathway in a NLR Nod1-
dependent manner in response to H. pylori peptidoglycan,
which is injected into the host cell cytoplasm via the T4SS
[5]. This activation leads to IL-8 secretion. Other pathogen-
recognition molecules, such as TLR2, TLR4 and TLR5,
which sense speciﬁc Gram-negative bacterial components,
including lipoproteins, lipopolysaccharide and ﬂagellin,
respectively, appear to play a minor role in the recognition
of H. pylori by gastric epithelial cells [40]. However,
miR-146a and miR-155 are not expressed in gastric epithe-
lial cells during infection, raising the question of which
miRNAs (if any) are involved in feedback regulation of
NF-jB in those cells.
Myeloid cells (monocyte/macrophage and dendritic cells)
constitute the second line of defense, sensing H. pylori com-
ponents via TLR2, TLR4 or Nod1 signalling, and secrete
pro-inﬂammatory cytokines such as IL-6, IL-1b and TNF-a
in order to establish T and B lymphocyte-mediated adapta-
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tive immunity [40]. MiR-146a and miR-155 are likely to be
induced in myeloid and/or lymphocytes in response to the
bacterium. Notably, the oncogenic miR-155 [16] and miR-
17-92 [37] may deserve special attention in gastric MALT
lymphoma, resulting from H. pylori-induced uncontrolled B
cell proliferation.
Oncogenic miRNAs and H. pylori
Because speciﬁc miRNAs have been found up-regulated in
gastric carcinomas, the question of their deregulation in gas-
tric epithelium during H. pylori infection is obvious. As men-
tioned above, Zhang et al. [9] demonstrated a link between
H. pylori infection and miR-21. That study should now be
extended to other miRNAs implicated in gastric cancer, such
as the miR-106b-25 and miR-221-222 clusters. A clue could
be TGF-b, which is signiﬁcantly and speciﬁcally increased by
H. pylori in cultured gastric epithelial cells and monocytes.
This effect was attributed to a soluble protein of the bacteria
[34], which may, in this way, modulate the immune response,
contribute to the persistence of H. pylori infection, and dys-
regulate the physiological turnover of gastric epithelial cells.
MiR-27a was also identiﬁed as an oncogenic miRNA in a
gastric adenocarcinoma cell line, in which it targets the
tumour suppressor prohibitin, an evolutionary conserved and
ubiquitous protein interacting with pRb and its family mem-
bers [41]. Another miR-27a target, the zinc ﬁnger ZBTB10, a
transcriptional repressor of speciﬁcity protein (Sp) transcrip-
tion factors, has been identiﬁed in breast carcinoma cells [42].
Sp factors are over-expressed in tumours, notably in gastric
tumours, and contribute to the proliferative and angiogenic
phenotype associated with cancer cells. Inhibition of miR-27a
resulted in increased expression of ZBTB10 mRNA,
decreased expression of Sp factors, and cell cycle arrest. This
latter response was associated with the induction of Myt-1,
another miR-27a target, which blocks G2/M transition
through inactivation of the cdc2 cyclin-dependent kinase.
Thus, the oncogenic activity of miR-27a is a result, at least in
part, to the suppression of ZBTB10 and Myt-1. This mecha-
nism may be relevant to H. pylori-induced, CagA-dependent
progression to G2/M in gastric epithelial cells [43].
It is expected that multiple miRNAs may contribute to
tumour development and that some miRNAs may have
cooperative or redundant functions.
MiR-200 family and the epithelial-to-mesenchymal transition
(EMT)
H. pylori induces an invasive phenotype in epithelial cells that
resembles an EMT. Indeed, CagA, once injected into the host
cell, changes the epithelial cell morphology by disrupting
cell–cell junctions and inducing loss of apical–basolateral
polarity [2]. By its interaction with several junction proteins,
including ZO-1, JAM and E-cadherin, CagA disturbs the
assembly and function of both tight and adherent junctions
[2]. Its interaction with E-cadherin leads to the release of
b-catenin complexed to E-cadherin and the subsequent
activation of the Wnt/b-catenin signalling pathway [51,52].
Deregulation of b-catenin plays a crucial role in gastrointesti-
nal cancers. Numerous targets of this transcription factor
have been described, including genes implicated in prolifera-
tion, tumour invasion and metastasis. Regarding the miRNAs,
a correlation between miR-375 repression and b-catenin-
activating mutation in hepatocellular adenoma and carcinoma
has been described [53]. However, the mechanism of this
repression remains to be elucidated. In addition, a direct
connection between E-cadherin and gastric carcinogenesis
has been demonstrated through the ﬁnding that genetic
mutations in CDH1, the gene encoding E-cadherin, are
associated with hereditary diffuse gastric cancer [44]. The
miR-200 family, which includes miR-200a, b, c, miR-141 and
miR-429, inhibits EMT and invasion in cancer cells [45–48].
All of these members are implicated in a negative regulation
loop, in which they repress the E-cadherin transcriptional
repressors ZEB1 and ZEB2/SIP1 (Zinc-ﬁnger E-box Binding
homeobox 1 and 2), themselves down-regulating the miR-
200 family transcription. The expression of these miRNAs is
lost in invasive cancer cells harbouring a mesenchymal
phenotype. Moreover, ZEB2/SIP1 also represses cyclin D1
transcription [49]. This cyclin, which promotes G1/S
transition, is induced via AP-1 and the cAMP-response
element in gastric epithelial cells during H. pylori infection
and under CagA dependence [50]. Therefore, a role of the
miR-200 family and ZEB repressors is likely in the EMT-like
phenotype observed in H. pylori-infected cells.
Conclusions
The miRNA family has recently emerged to challenge the
accepted paradigm of gene regulation by the combinatorial
action of transcriptional factors activating or repressing spe-
ciﬁc genes. It has been proposed that they can act as devel-
opmental switches and fail-safe regulators of transcriptional
programmes. Regulatory loops can be established between
genes coding for classical transcriptional factors and genes
coding for miRNAs. It should be noted that, for a compre-
hensive understanding of the role of a given miRNA, the
direct relationship between a miRNA and the expression of
a particular target may be more important in some situations
than in others, depending on the cellular context. Conse-
quently, the therapeutic potential of miRNAs may be strictly
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associated with the occurrence of speciﬁc miRNA-dependent
function alterations. Further exploration of miRNA-mediated
gene silencing, taking into account the host miRNA/host tar-
get/bacterial effector relationship, most certainly will bring
new insights into how these small regulatory RNAs modulate
gene expression in human cells that chronically harbour
H. pylori.
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